In context
Bremelanotide acts on melanocortin receptors. The US-labelled product Vyleesi is for a defined form of low sexual desire in premenopausal women, not general sexual performance enhancement. [1]
At a glance
- Type
- Peptide medicine
- Regulatory context
- United States: Vyleesi is labelled for acquired, generalised hypoactive sexual desire disorder in premenopausal women, with exclusions and limitations.
- Evidence
- A labelled medicine has evidence for its stated population and use; this does not validate every marketed version or proposed use.
What is it?
A melanocortin-receptor medicine. Its clinical context is specific: the diagnosis must not be explained by another medical or psychiatric condition, relationship problems, or a medicine. [1]
What the evidence does not establish
The Vyleesi indication does not include men, postmenopausal women or enhancement of sexual performance. PT-141 is a name commonly associated with bremelanotide, not a separate approval. [1]
Safety and clinical context
The prescribing information contains eligibility limits and precautions. Clinical evaluation must distinguish the indicated condition from other causes of low desire.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- Vyleesi prescribing information — US label dailymed.nlm.nih.gov